Broadly neutralizing antibodies and vaccine design against HIV-1 infection

Remarkable progress has been achieved for prophylactic and therapeutic interventions against human immunodeficiency virus type I(HIV-1)through antiretroviral therapy.However,vaccine development has remained challenging.Recent discoveries in broadly neutralizing monoclonal antibodies(bNAbs)has led to the development of multiple novel vaccine approaches for inducing bNAbs-like antibody response.Structural and dynamic studies revealed several vulnerable sites and states of the HIV-1 envelop glycoprotein(Env)during infection.Our review aims to highlight these discoveries and rejuvenate our endeavor in HIV-1 vaccine design and development.

Immunity:研究开发出最优的HIV疫苗递送模式

HIV已不再占据头条新闻。这主要是因为抗逆转录病毒药物的成功开发已将HIV病毒感染导致的艾滋病（AIDS）转化为一种慢性的可控制的疾病。然而。当前在全世界大约0．367亿名HIV感染者中，仅约一半的人能够获得控制这种病毒所需的药物。与此同时。新的HIV感染率持续保持在非常高的水平，这突出强调了需要开发一种预防性疫苗。然而，几十年来。